Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
+2.38%
$5.73
100% positive prob.
5-Day Prediction
+13.56%
$6.36
100% positive prob.
20-Day Prediction
+24.96%
$7.00
95% positive prob.
| Quarter | Signal | 1D Return | 5D Return | 20D Return | Confidence | Actual 5D |
|---|---|---|---|---|---|---|
| Q2 2026 | BUY | +2.38% | +13.56% | +24.96% | 100.0% | -9.64% |
| Q4 2025 | BUY | +2.38% | +13.56% | +24.96% | 100.0% | -9.99% |
SEC 8-K filings with transcript text
Jul 6, 2026 · 100% conf.
1D
+2.38%
$5.73
Act: +0.36%
5D
+13.56%
$6.36
Act: -9.64%
20D
+24.96%
$7.00
2 rxst-ex99_1.htm
Exhibit 99.1
RXSIGHT, INC. ANNOUNCES PRELIMINARY SECOND QUARTER FINANCIAL RESULTS AND PRODUCT PIPELINE UPDATES FOLLOWING STRATEGIC COLLABORATION AGREEMENT
Aliso Viejo, Calif. – July 6, 2026 – RxSight, Inc. (NASDAQ: RXST) today announced select preliminary financial results for the second quarter of 2026 and updates to its standalone product pipeline, following the announcement of the company’s strategic collaboration with Alcon to develop and commercialize light-adjustable Presbyopia-Correcting Intraocular Lenses.
Preliminary Second Quarter 2026 Results
• Total company revenue is expected to be approximately $32 to $34 million, which includes,
o $5 to $7 million in revenue recognized from the RxSight Alcon Strategic Collaboration, with the specific amount expected to be reported with the Company’s financial results for the second quarter of 2026 in August 2026.
• Sales of approximately $27 million, which includes,
o the sale of 24,917 Light Adjustable Lens (LAL®) units; and
o 11 Light Delivery Devices (LDD™) units; 1 rental unit placed.
• Cash, cash equivalents and short-term investments of approximately $209 million as of June 30, 2026.
Pipeline Highlights
• Next-generation RxSight Light Adjustable Technology™ platform, with intermediate-term launches of new LAL®, LAL +®, and LAL Toric lenses with improved workflow and fewer required post-operative treatments.
• Collaboration with Alcon to innovate our respective platforms to develop and commercialize light-adjustable Presbyopia-Correcting Intraocular Lenses (Simultaneous Vision Intraocular Lenses).
“While we faced meaningful commercial headwinds in Q2, including from more widespread competitive trialing, the unique ability of RxSight’s Light Adjustable Technology to customize visual outcomes continued to deliver significant clinical benefits to thousands of patients around the world,” said Dr. Ron Kurtz, Chief Executive Officer and President of RxSight. “To position the company for deeper penetration of current, next-generation, and collaboration products, we are accelerating investments in our LAL sales force and commercial capabilities, while maintaining a disciplined approach to overall spending. By leveraging our differentiated technology, large customer base, strong balance sheet and exciting pipeline, we believe RxSight is well positioned to drive both high-margin implant sales and future royalty income, thereby empowering doctors to deliver the industry’s premier outcomes for even more of their patients.”
Updated Product Pipeline
RxSight is developing the first and only suite of adjustable IOLs built on its next-generation Light Adjustable Lens technology platform with improved workflow and enhanced performance. Highlights include:
• Next-generation LAL, designed to deliver best-in-class visual quality and optical clarity, with post-operative refractive optimization to consistently achieve targeted visual outcomes;
• Next-generation LAL+, designed to improve intermediate vision for everyday activities while preserving high-quality optical performance, with adjustability enabling precise refractive targeting;
• LAL Toric, designed with built-in astigmatism correction, while still enabling post-operative refinement of residual sphere and cylinder to maximize uncorrected visual acuity.
Updated 2026 Guidance
• 2026 full-year revenue of $140 to $160 million, inclusive of RxSight sales and revenue recognized from the RxSight Alcon Strategic Collaboration, comprised of:
o Sales of $110 to $120 million, below previous guidance of $120 to $135 million
o Collaboration Agreement revenue of $30 to $40 million, subject to the terms and conditions described in the Current Report on Form 8-K filed with the Securities and Exchange Commission (SEC) on or about the date hereof;
• Gross margin of 73% to 75%, above previous guidance of 70% to 72%; and
• Operating expense at the high-end of $150 to $160 million, in line with previous guidance
The foregoing financial and operational results are preliminary estimates. RxSight is in the process of finalizing its financial statements for the second quarter of 2026, and its actual results remain subject to completion of those financial statements and their review by its independent registered public accounting firm. These preliminary estimates are based on information available to management as of the date of this press release and certain related assumptions, which could prove incorrect. RxSight’s actual, reported results of operations could differ based on completion of our quarter end closing procedures, final adjustments and developments that may arise prior to completion of its quarterly financial statements, and adjustments arising from the review by its independent registered public accounting firm. You should carefully review RxSight’s unaudited, consolidated financial statements for the second quarter of 2026 when they become available.
Conferenc
May 6, 2026
2 rxst-ex99_1.htm
Exhibit 99.1
RXSIGHT, INC. REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES FULL-YEAR SALES OUTLOOK
Aliso Viejo, Calif. – May 6, 2026 – RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended March 31, 2026.
Strategic Highlights and Recent Developments
• Q1 sales of $30.9 million driven by 27,472 Light Adjustable Lens (LAL) units
• 20 Light Delivery Devices (LDDs) sold in Q1, expanding the installed base to 1,154 units
• Robust clinical data presented at the recent American Society of Cataract and Refractive Surgery (ASCRS) annual meeting highlighting the versatility and impact of adjustability
• Recent regulatory approval in New Zealand furthering the company’s international footprint and global market opportunity
• 2026 sales and gross margin guidance unchanged; operating expense expected to be at high end of previous range reflecting targeted investments in strategic growth initiatives
“We are encouraged by the stabilizing business trends and the initial progress from our ongoing commercial initiatives,” said Ron Kurtz, President and Chief Executive Officer of RxSight. “As we continue to refine these efforts, investing in both our team and our pipeline, we are confident that we can continue to build momentum across the company and reach the full potential of our technology for patients and practices.”
First Quarter Financial Results
In the first quarter of 2026, the company reported sales of $30.9 million, down 18.5% compared to the prior year, largely reflecting lower LDD unit volumes, consistent with expectations. LAL procedures decreased 0.4% year over year.
First quarter gross profit margin of 76.1% increased from 74.8% in the prior‑year period, primarily driven by a favorable shift in product mix toward LAL sales.
Total operating expenses were $41.3 million versus $39.0 million in the year-ago period. The increase was primarily driven by the continued expansion of our global commercial and support teams.
In the first quarter of 2026, the company reported a net loss of $(15.9) million, or $(0.38) per basic and diluted share, compared to a net loss of $(8.2) million, or $(0.20) per basic and diluted share in the first quarter of 2025. Adjusted net loss in the first quarter of 2026 was $(7.9) million, or $(0.19) per basic and diluted share, compared to an adjusted net loss of $(1.1) million, or $(0.03) per basic and diluted share in the first quarter of 2025.
As of March 31, 2026, cash, cash equivalents and short-term investments totaled $217.9 million.
2026 ASCRS Highlights
At the recent ASCRS annual meeting, RxSight technology was featured across multiple scientific presentations addressing refractive accuracy, complex cases and evolving treatment strategies. This rapidly expanding body of clinical evidence highlighted both the versatility and impact of adjustability. In addition, the conference included presentations by Dr. Szabo, who reported binocular LAL outcomes in which 93.1% of patients achieved simultaneous 20/20 or better distance and J1 or better near, as well as a meta-analysis by Dr. Rabinovitch, demonstrating pooled accuracy with the LAL was 91.2% within 0.50 diopters of target refraction.
2026 Guidance
The company’s 2026 financial guidance is as follows:
• Revenue of $120 to $135 million, in-line with previous guidance
• Gross margin of 70% to 72%, in-line with previous guidance
• Operating expenses expected to be at the high-end of previous $150 to $160 million range
• Non-cash stock-based compensation expense of $30 to $32 million, in-line with previous guidance
Conference Call
On Wednesday, May 6, 2026, at 1:30 p.m. Pacific Time, the company will host a conference call to discuss its first quarter 2026 financial results. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963 and enter the conference code: 2630350. The call will also be broadcast live in listen-only mode via a link on the company’s investor relations website at https://investors.rxsight.com/. An archived recording of the call will be available through the same link shortly after its completion.
About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens (LAL/LAL+, collectively the “LAL”), RxSight Light Delivery Device (LDD) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.
This press release contains forward-looking statements, including: including statements regarding the company’s expectations related to stabilizing busin
Feb 25, 2026 · 100% conf.
1D
+2.38%
$9.02
Act: -10.10%
5D
+13.56%
$10.00
Act: -9.99%
20D
+24.96%
$11.01
8-K
false000111148500011114852026-02-252026-02-25
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 25, 2026
RxSight, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-40690
94-3268801
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
100 Columbia
Aliso Viejo, California
92656
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (949) 521-7830
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On February 25, 2026, RxSight, Inc. (the “Company”) issued a press release announcing its results of operations and financial condition for the three and twelve months ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information furnished in this Current Report on Form 8-K under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or in any filing under the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits. The following exhibit is furnished as part of this report:
Exhibit number
Description
99.1
Press Release dated February 25, 2026.
104
Cover Page Interactive Data File (embedded within the inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
RxSight, Inc.
Date:
February 25, 2026
By:
/s/ Mark Wilterding
Name: Mark Wilterding Title: Chief Financial Officer
Jan 12, 2026 · 100% conf.
1D
+2.38%
$9.02
Act: -10.10%
5D
+13.56%
$10.00
Act: -9.99%
20D
+24.96%
$11.01
8-K
false000111148500011114852026-01-112026-01-11
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 11, 2026
RxSight, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-40690
94-3268801
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
100 Columbia
Aliso Viejo, California
92656
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (949) 521-7830
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On January 11, 2026, RxSight, Inc. (the “Company”) issued a press release announcing certain preliminary unaudited fourth quarter and full-year 2025 financial and operational results. A copy of the press release is furnished herewith as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the information furnished in this Current Report on Form 8-K under Item 2.02 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or in any filing under the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 13, 2025, the Company appointed Mark Wilterding as its Chief Financial Officer (and principal financial and accounting officer), effective January 11, 2026 (the “Effective Date”), replacing Shelley Thunen in such capacities. Prior to joining the Company, Mr. Wilterding, age 48, served as the senior vice president, global finance for Edwards Lifesciences, a leading global structural heart innovation company, from March 2025 to January 2026. In this role Mr. Wilterding maintained responsibility for Financial Planning and Analysis (FP&A), treasury, regional finance, investor relations and financial operations & strategy. Prior to his most recent position with Edwards Lifesciences, Mr. Wilterding served in various roles at Edwards Lifesciences beginning in June 2019, including senior vice president, investor relations, FP&A, and treasurer. From April 2014 to June 2019, Mr. Wilterding served as director, investor relations of Medtronic, a global healthcare technology company. Mr. Wilterding holds a bachelor’s degree in economics and English from St. Olaf College and an M.B.A. in finance, management and strategy, and marketing from the Kellogg School of Management at Northwestern University. In connection with his appointment, Mr. Wilterding entered into a confirmatory employment letter, dated December 15, 2025, effective as of January 11, 2026 (the “Employment Agreement”). Pursuant to the terms of the Employment Agreement, Mr. Wilterding will receive an annual base salary of $550,000 and will be eligible to receive an annual bonus of up to 65% of his annual base salary. Mr. Wilterding is also entitled to receive a sign-on bonus in an amount to be determined based on terms specified in the Employment Agreement. Mr. Wilterding is eligible to participate in employee benefit plans generally available to other senior executives of the Company. Pursuant to the Employment Agreement, Mr. Wilterding entered into the Company’s Proprietary Information and Inventions A
Nov 5, 2025
8-K
0001111485false00011114852025-11-052025-11-05
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 05, 2025
RxSight, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-40690
94-3268801
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
100 Columbia
Aliso Viejo, California
92656
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (949) 521-7830
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On November 5, 2025, RxSight, Inc. (the “Company”) issued a press release announcing its results of operations and financial condition for the three and nine months ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information furnished in this Current Report on Form 8-K under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or in any filing under the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits. The following exhibit is furnished as part of this report:
Exhibit number
Description
99.1
Press Release dated November 5, 2025.
104
Cover Page Interactive Data File (embedded within the inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
RxSight, Inc.
Date:
November 5, 2025
By:
/s/ Shelley Thunen
Name: Shelley Thunen Title: Co-President and Chief Financial Officer
Aug 7, 2025
8-K
0001111485false00011114852025-08-072025-08-07
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 07, 2025
RxSight, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-40690
94-3268801
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
100 Columbia
Aliso Viejo, California
92656
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (949) 521-7830
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On August 7, 2025, RxSight, Inc. (the “Company”) issued a press release announcing its results of operations and financial condition for the three and six months ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information furnished in this Current Report on Form 8-K under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or in any filing under the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits. The following exhibit is furnished as part of this report:
Exhibit number
Description
99.1
Press Release dated August 7, 2025.
104
Cover Page Interactive Data File (embedded within the inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
RxSight, Inc.
Date:
August 7, 2025
By:
/s/ Shelley Thunen
Name: Shelley Thunen Title: Co-President and Chief Financial Officer
Jul 8, 2025
8-K
0001111485false00011114852025-07-082025-07-08
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 08, 2025
RxSight, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-40690
94-3268801
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
100 Columbia
Aliso Viejo, California
92656
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (949) 521-7830
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On July 8, 2025, RxSight, Inc. (the “Company”) issued a press release announcing certain preliminary unaudited second quarter financial and operational results. A copy of the press release is furnished herewith as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the information furnished in this Current Report on Form 8-K under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or in any filing under the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
Exhibit number
Description
99.1
Press Release dated July 8, 2025.
104
Cover Page Interactive Data File (embedded within the inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
RxSight, Inc.
Date:
July 8, 2025
By:
/s/ Shelley Thunen
Name: Shelley Thunen Title: Co-President and Chief Financial Officer
May 7, 2025
8-K
0001111485false00011114852025-05-072025-05-07
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 07, 2025
RxSight, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-40690
94-3268801
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
100 Columbia
Aliso Viejo, California
92656
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (949) 521-7830
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On May 7, 2025, RxSight, Inc. (the “Company”) issued a press release announcing its results of operations and financial condition for the three ended March 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information furnished in this Current Report on Form 8-K under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or in any filing under the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits. The following exhibit is furnished as part of this report:
Exhibit number
Description
99.1
Press Release dated May 7, 2025.
104
Cover Page Interactive Data File (embedded within the inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
RxSight, Inc.
Date:
May 7, 2025
By:
/s/ Shelley Thunen
Name: Shelley Thunen Title: Co-President and Chief Financial Officer
Apr 3, 2025
8-K
0001111485false00011114852025-04-022025-04-02
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 02, 2025
RxSight, Inc.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-40690
94-3268801
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
100 Columbia
Aliso Viejo, California
92656
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (949) 521-7830
,
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On April 2, 2025, RxSight, Inc. (the “Company”) issued a press release announcing certain preliminary unaudited first quarter financial and operational results. A copy of the press release is furnished herewith as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the information furnished in this Current Report on Form 8-K under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or in any filing under the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
Exhibit number
Description
99.1
Press Release dated April 2, 2025.
104
Cover Page Interactive Data File (embedded within the inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
RxSight, Inc.
Date:
April 2, 2025
By:
/s/ Shelley Thunen
Name: Shelley Thunen Title: Co-President and Chief Financial Officer
Feb 25, 2025
8-K
false000111148500011114852025-02-252025-02-25
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 25, 2025
RxSight, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-40690
94-3268801
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
100 Columbia
Aliso Viejo, California
92656
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (949) 521-7830
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On February 25, 2025, RxSight, Inc. (the “Company”) issued a press release announcing its results of operations and financial condition for the three and twelve months ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information furnished in this Current Report on Form 8-K under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or in any filing under the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits. The following exhibit is furnished as part of this report:
Exhibit number
Description
99.1
Press Release dated February 25, 2025.
104
Cover Page Interactive Data File (embedded within the inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
RxSight, Inc.
Date:
February 25, 2025
By:
/s/ Shelley Thunen
Name: Shelley Thunen Title: Co-President and Chief Financial Officer
Jan 13, 2025
8-K
0001111485false00011114852025-01-122025-01-12
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 12, 2025
RxSight, Inc.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-40690
94-3268801
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
100 Columbia
Aliso Viejo, California
92656
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (949) 521-7830
,
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On January 12, 2025, RxSight, Inc. (the “Company”) issued a press release announcing certain preliminary unaudited fourth quarter and full-year 2024 financial and operational results. A copy of the press release is furnished herewith as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the information furnished in this Current Report on Form 8-K under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or in any filing under the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
Exhibit number
Description
99.1
Press Release dated January 12, 2025.
104
Cover Page Interactive Data File (embedded within the inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
RxSight, Inc.
Date:
January 13, 2025
By:
/s/ Shelley Thunen
Name: Shelley Thunen Title: Co-President and Chief Financial Officer
Nov 7, 2024
8-K
0001111485false00011114852024-11-072024-11-07
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 07, 2024
RxSight, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-40690
94-3268801
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
100 Columbia
Aliso Viejo, California
92656
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (949) 521-7830
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On November 7, 2024, RxSight, Inc. (the “Company”) issued a press release announcing its results of operations and financial condition for the three and nine months ended September 30, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information furnished in this Current Report on Form 8-K under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or in any filing under the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits. The following exhibit is furnished as part of this report:
Exhibit number
Description
99.1
Press Release dated November 7, 2024.
104
Cover Page Interactive Data File (embedded within the inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
RxSight, Inc.
Date:
November 7, 2024
By:
/s/ Shelley Thunen
Name: Shelley Thunen Title: Co-President and Chief Financial Officer
Aug 5, 2024
8-K
false000111148500011114852024-08-052024-08-05
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 05, 2024
RxSight, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-40690
94-3268801
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
100 Columbia
Aliso Viejo, California
92656
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (949) 521-7830
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On August 5, 2024, RxSight, Inc. (the “Company”) issued a press release announcing its results of operations and financial condition for the three and six months ended June 30, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information furnished in this Current Report on Form 8-K under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or in any filing under the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits. The following exhibit is furnished as part of this report:
Exhibit number
Description
99.1
Press Release dated August 5, 2024.
104
Cover Page Interactive Data File (embedded within the inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
RxSight, Inc.
Date:
August 5, 2024
By:
/s/ Shelley Thunen
Name: Shelley Thunen Title: Co-President and Chief Financial Officer
May 6, 2024
8-K
0001111485false00011114852024-05-062024-05-06
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 06, 2024
RxSight, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-40690
94-3268801
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
100 Columbia
Aliso Viejo, California
92656
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (949) 521-7830
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On May 6, 2024, RxSight, Inc. (the “Company”) issued a press release announcing its results of operations and financial condition for the three months ended March 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information furnished in this Current Report on Form 8-K under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or in any filing under the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits. The following exhibit is furnished as part of this report:
Exhibit number
Description
99.1
Press Release dated May 6, 2024.
104
Cover Page Interactive Data File (embedded within the inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
RxSight, Inc.
Date:
May 6, 2024
By:
/s/ Shelley Thunen
Name: Shelley Thunen Title: Chief Financial Officer
Feb 28, 2024
8-K
0001111485false00011114852024-02-282024-02-28
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 28, 2024
RxSight, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-40690
94-3268801
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
100 Columbia
Aliso Viejo, California
92656
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (949) 521-7830
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On February 28, 2024, RxSight, Inc. (the “Company”) issued a press release announcing its results of operations and financial condition for the three and twelve months ended December 31, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information furnished in this Current Report on Form 8-K under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or in any filing under the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits. The following exhibit is furnished as part of this report:
Exhibit number
Description
99.1
Press Release dated February 28, 2024.
104
Cover Page Interactive Data File (embedded within the inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
RxSight, Inc.
Date:
February 28, 2024
By:
/s/ Shelley Thunen
Name: Shelley Thunen Title: Chief Financial Officer
Jan 8, 2024
8-K
false000111148500011114852024-01-072024-01-07
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 07, 2024
RxSight, Inc.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-40690
94-3268801
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
100 Columbia
Aliso Viejo, California
92656
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (949) 521-7830
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On January 7, 2024, RxSight, Inc. (the “Company”) issued a press release announcing certain preliminary unaudited fourth quarter and full-year 2023 financial and operational results. A copy of the press release is furnished herewith as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the information furnished in this Current Report on Form 8-K under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or in any filing under the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
Exhibit number
Description
99.1
Press Release dated January 7, 2024.
104
Cover Page Interactive Data File (embedded within the inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
RxSight, Inc.
Date:
January 8, 2024
By:
/s/ Shelley Thunen
Name: Shelley Thunen Title: Chief Financial Officer
Nov 9, 2023
8-K
false000111148500011114852023-11-092023-11-09
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 09, 2023
RxSight, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-40690
94-3268801
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
100 Columbia
Aliso Viejo, California
92656
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (949) 521-7830
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 2.02 Results of Operations and Financial Condition. On November 9, 2023, RxSight, Inc. (the “Company”) issued a press release announcing its results of operations and financial condition for the three and nine months ended September 30, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information furnished in this Current Report on Form 8-K under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or in any filing under the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits. The following exhibit is furnished as part of this report:
Exhibit number
Description
99.1
Press Release dated November 9, 2023.
104
Cover Page Interactive Data File (embedded within the inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
RxSight, Inc.
Date:
November 9, 2023
By:
/s/ Shelley Thunen
Name: Shelley Thunen Title: Chief Financial Officer
Aug 7, 2023
8-K
false000111148500011114852023-08-072023-08-07
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 07, 2023
RxSight, Inc.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-40690
94-3268801
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
100 Columbia
Aliso Viejo, California
92656
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (949) 521-7830
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 2.02 Results of Operations and Financial Condition.
On August 7, 2023, RxSight, Inc. (the “Company”) issued a press release announcing its results of operations and financial condition for the three and six months ended June 30, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information furnished in this Current Report on Form 8-K under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or in any filing under the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
The following exhibit is furnished as part of this report:
Exhibit number
Description
99.1
Press Release dated August 7, 2023.
104
Cover Page Interactive Data File (embedded within the inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
RxSight, Inc.
Date:
August 7, 2023
By:
/s/ Shelley Thunen
Name: Shelley Thunen Title: Chief Financial Officer
May 9, 2023
8-K
0001111485false00011114852023-05-092023-05-09
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 09, 2023
RxSight, Inc.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-40690
94-3268801
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
100 Columbia
Aliso Viejo, California
92656
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: 949 521-7830
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 2.02 Results of Operations and Financial Condition.
On May 9, 2023, RxSight, Inc. (the “Company”) issued a press release announcing its results of operations and financial condition for the three months ended March 31, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information furnished in this Current Report on Form 8-K under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or in any filing under the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
The following exhibit is furnished as part of this report:
Exhibit number
Description
99.1
Press Release dated May 9, 2023.
104
Cover Page Interactive Data File (embedded within the inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
RxSight, Inc.
Date:
May 9, 2023
By:
/s/ Shelley Thunen
Name: Shelley Thunen Title: Chief Financial Officer
Mar 6, 2023
8-K
0001111485false00011114852023-03-062023-03-06
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 06, 2023
RxSight, Inc.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-40690
94-3268801
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
100 Columbia
Aliso Viejo, California
92656
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: 949 521-7830
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 2.02 Results of Operations and Financial Condition.
On March 6, 2023, RxSight, Inc. (the “Company”) issued a press release announcing its results of operations and financial condition for the three and twelve-months ended December 31, 2022. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information furnished in this Current Report on Form 8-K under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or in any filing under the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
The following exhibit is furnished as part of this report:
Exhibit number
Description
99.1
Press Release dated March 6, 2023.
104
Cover Page Interactive Data File (embedded within the inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
RxSight, Inc.
Date:
March 6, 2023
By:
/s/ Shelley Thunen
Name: Shelley Thunen Title: Chief Financial Officer
This page provides RxSight Inc. (RXST) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on RXST's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.